Regeneron gets FDA priority review for Ebola sibling of COVID-19 prospect

The FDA has accepted Regeneron’s filing for approval of the Ebola drug REGN-EB3 for priority review. REGN-EB3, which comes from the same platform as Regeneron’s COVID-19 antibodies, arrives at the FDA after outperforming ZMapp in a clinical trial.